{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:11:49Z","timestamp":1793722309623,"version":"4.6.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40261-025-01436-9","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T14:31:19Z","timestamp":1743863479000},"page":"235-245","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria: A Systematic Review and Meta-analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"45","author":[{"given":"Ana Carolina Putini","family":"Vieira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Carolina","family":"Ventura de Santana de Jesus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anelise Poluboiarinov","family":"Cappellaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas M.","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Clara Felix","family":"de Farias Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina Mira Dilly","family":"de Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mable","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel Gomes","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9861-0670","authenticated-orcid":false,"given":"Fernanda Valeriano","family":"Zamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"key":"1436_CR1","doi-asserted-by":"publisher","unstructured":"Zuberbier T. Chronic spontaneous urticaria guidelines: what is new? J Allergy Clin Immunol. 2022;150(6):1249\u201355. https:\/\/doi.org\/10.1016\/j.jaci.2022.10.004. Erratum in: J Allergy Clin Immunol. 2023 Feb;151(2):580. https:\/\/doi.org\/10.1016\/j.jaci.2022.12.804.","DOI":"10.1016\/j.jaci.2022.10.004 10.1016\/j.jaci.2022.12.804"},{"issue":"1","key":"1436_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41572-022-00389-z","volume":"8","author":"P Kolkhir","year":"2022","unstructured":"Kolkhir P, Gim\u00e9nez-Arnau AM, Kulthanan K, Peter J, Metz M, Maurer M. Urticaria Nat Rev Dis Primers. 2022;8(1):61. https:\/\/doi.org\/10.1038\/s41572-022-00389-z.","journal-title":"Urticaria. Nat Rev Dis Primers"},{"key":"1436_CR3","doi-asserted-by":"publisher","unstructured":"Maurer M. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy. 2011;66(3):317\u201330. https:\/\/doi.org\/10.1111\/j.1398-9995.2010.02496.x.","DOI":"10.1111\/j.1398-9995.2010.02496.x"},{"issue":"8","key":"1436_CR4","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1080\/14712598.2020.1767061","volume":"20","author":"B Wedi","year":"2020","unstructured":"Wedi B. Ligelizumab for the treatment of chronic spontaneous urticaria. Expert Opin Biol Ther. 2020;20(8):853\u201361. https:\/\/doi.org\/10.1080\/14712598.2020.1767061.","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"1436_CR5","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/j.jaci.2022.04.010","volume":"149","author":"P Kolkhir","year":"2022","unstructured":"Kolkhir P, Mu\u00f1oz M, Asero R, Ferrer M, Kocat\u00fcrk E, Metz M, Xiang YK, Maurer M. Autoimmune chronic spontaneous urticaria. J Allergy Clin Immunol. 2022;149(6):1819\u201331. https:\/\/doi.org\/10.1016\/j.jaci.2022.04.010.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1436_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/all.12056","volume":"68","author":"GN Konstantinou","year":"2013","unstructured":"Konstantinou GN, Asero R, Ferrer M, Knol EF, Maurer M, Raap U, Schmid-Grendelmeier P, Skov PS, Grattan CE. EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria. Allergy. 2013;68(1):27\u201336.","journal-title":"Allergy"},{"issue":"6","key":"1436_CR7","doi-asserted-by":"publisher","first-page":"816","DOI":"10.3390\/medicina58060816","volume":"58","author":"OA Orzan","year":"2022","unstructured":"Orzan OA, Popa LG, Mihai MM, Cojocaru A, Giurc\u0103neanu C, Doroban\u021bu AM. Current and future approaches in management of chronic spontaneous urticaria using anti-IgE antibodies. Medicina (Kaunas). 2022;58(6):816. https:\/\/doi.org\/10.3390\/medicina58060816.","journal-title":"Medicina (Kaunas)"},{"issue":"11","key":"1436_CR8","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1001\/jamadermatol.2021.3237","volume":"157","author":"S Nochaiwong","year":"2021","unstructured":"Nochaiwong S, Chuamanochan M, Ruengorn C, Awiphan R, Tovanabutra N, Chiewchanvit S. Evaluation of pharmacologic treatments for H1 antihistamine-refractory chronic spontaneous urticaria: a systematic review and network meta-analysis. JAMA Dermatol. 2021;157(11):1316\u201327. https:\/\/doi.org\/10.1001\/jamadermatol.2021.3237.","journal-title":"JAMA Dermatol"},{"key":"1436_CR9","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024. http:\/\/www.training.cochrane.org\/handbook. Accessed Jan 30 2025."},{"key":"1436_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"issue":"14","key":"1436_CR11","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1056\/NEJMoa1900408","volume":"381","author":"M Maurer","year":"2019","unstructured":"Maurer M, Gim\u00e9nez-Arnau AM, Sussman G, Metz M, Baker DR, Bauer A, Bernstein JA, Brehler R, Chu CY, Chung WH, Danilycheva I, Grattan C, H\u00e9bert J, Katelaris C, Makris M, Meshkova R, Savic S, Sinclair R, Sitz K, Staubach P, Wedi B, L\u00f6ffler J, Barve A, Kobayashi K, Hua E, Severin T, Janocha R. Ligelizumab for chronic spontaneous urticaria. N Engl J Med. 2019;381(14):1321\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1900408.","journal-title":"N Engl J Med"},{"key":"1436_CR12","doi-asserted-by":"publisher","unstructured":"Maurer M, Ensina LF, Gimenez-Arnau AM, Sussman G, Hide M, Saini S, Grattan C, Fomina D, Rigopoulos D, Berard F, Canonica GW, Rockmann H, Irani C, Szepietowski JC, Leflein J, Bernstein JA, Peter JG, Kulthanan K, Godse K, Ardusso L, Ukhanova O, Staubach P, Sinclair R, Gogate S, Thomsen SF, Tanus T, Ye YM, Burciu A, Barve A, Modi D, Scosyrev E, Hua E, Letzelter K, Varanasi V, Patekar M, Severin T; PEARL-1 and PEARL-2 trial investigators. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials. Lancet. 2024;403(10422):147\u201359. https:\/\/doi.org\/10.1016\/S0140-6736(23)01684-7.","DOI":"10.1016\/S0140-6736(23)01684-7"},{"issue":"7","key":"1436_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/pai.13982","volume":"34","author":"P Staubach","year":"2023","unstructured":"Staubach P, Alvaro-Lozano M, Sekerel BE, Maurer M, Ben-Shoshan M, Porter M, Hua E, Ji Y, Burciu A, Savelieva M, Severin T, Drollmann A, Bienczak A. Ligelizumab in adolescents with chronic spontaneous urticaria: results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis. Pediatr Allergy Immunol. 2023;34(7): e13982. https:\/\/doi.org\/10.1111\/pai.13982.","journal-title":"Pediatr Allergy Immunol"},{"key":"1436_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JA Sterne","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomized trials. BMJ. 2019;366: l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"issue":"5","key":"1436_CR15","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1111\/jep.13016","volume":"24","author":"M Mercuri","year":"2018","unstructured":"Mercuri M, Gafni A. The evolution of GRADE (part 3): a framework built on science or faith? J Eval Clin Pract. 2018;24(5):1223\u201331.","journal-title":"J Eval Clin Pract"},{"issue":"2","key":"1436_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12121","volume":"12","author":"A Gim\u00e9nez-Arnau","year":"2022","unstructured":"Gim\u00e9nez-Arnau A, Maurer M, Bernstein J, Staubach P, Barbier N, Hua E, Severin T, Joubert Y, Janocha R, Balp MM. Ligelizumab improves sleep interference and disease burden in patients with chronic spontaneous urticaria. Clin Transl Allergy. 2022;12(2): e12121. https:\/\/doi.org\/10.1002\/clt2.12121.","journal-title":"Clin Transl Allergy."},{"issue":"1","key":"1436_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41467-019-13815-w","volume":"11","author":"P Gasser","year":"2020","unstructured":"Gasser P, Tarchevskaya SS, Guntern P, Brigger D, Ruppli R, Zb\u00e4ren N, Kleinboelting S, Heusser C, Jardetzky TS, Eggel A. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nat Commun. 2020;11(1):165. https:\/\/doi.org\/10.1038\/s41467-019-13815-w.","journal-title":"Nat Commun"},{"key":"1436_CR18","doi-asserted-by":"publisher","unstructured":"Eggel A, Pennington LF, Jardetzky TS. Therapeutic monoclonal antibodies in allergy: targeting IgE, cytokine, and alarmin pathways. Immunol Rev. 2024. https:\/\/doi.org\/10.1111\/imr.13380.","DOI":"10.1111\/imr.13380"},{"issue":"9","key":"1436_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2022.100690","volume":"15","author":"RA Wood","year":"2022","unstructured":"Wood RA, Chinthrajah RS, Eggel A, Bottoli I, Gautier A, Woisetschlaeger M, Tassinari P, Altman P. The rationale for development of ligelizumab in food allergy. World Allergy Organ J. 2022;15(9):100690. https:\/\/doi.org\/10.1016\/j.waojou.2022.100690.","journal-title":"World Allergy Organ J"},{"issue":"1","key":"1436_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2500\/aap.2023.44.220093","volume":"44","author":"TT Do","year":"2023","unstructured":"Do TT, Canty EA, Joshi SR. Current and future management of chronic spontaneous urticaria and chronic inducible urticaria. Allergy Asthma Proc. 2023;44(1):3\u201314. https:\/\/doi.org\/10.2500\/aap.2023.44.220093.","journal-title":"Allergy Asthma Proc"},{"key":"1436_CR21","doi-asserted-by":"publisher","unstructured":"Casale TB, Gimenez-Arnau AM, Bernstein JA, Holden M, Zuberbier T, Maurer M. Omalizumab for patients with chronic spontaneous urticaria: a narrative review of current status. Dermatol Ther (Heidelb). 2023;13(11):2573\u201388. https:\/\/doi.org\/10.1007\/s13555-023-01040-9.","DOI":"10.1007\/s13555-023-01040-9"},{"key":"1436_CR22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/5584_2020_612","volume":"12","author":"M Folci","year":"2020","unstructured":"Folci M, Ramponi G, Brunetta E. A comprehensive approach to urticaria: from clinical presentation to modern biological treatments through pathogenesis. Cell Biol Transl Med. 2020;12:111\u201337. https:\/\/doi.org\/10.1007\/5584_2020_612.","journal-title":"Cell Biol Transl Med"},{"issue":"2","key":"1436_CR23","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.jaci.2017.06.032","volume":"141","author":"M Maurer","year":"2018","unstructured":"Maurer M, Metz M, Brehler R, Hillen U, Jakob T, Mahler V, Pf\u00f6hler C, Staubach P, Treudler R, Wedi B, Magerl M. Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence. J Allergy Clin Immunol. 2018;141(2):638\u201349. https:\/\/doi.org\/10.1016\/j.jaci.2017.06.032.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1436_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jdermsci.2013.08.011","volume":"73","author":"M Metz","year":"2014","unstructured":"Metz M, Ohanyan T, Church MK, Maurer M. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. J Dermatol Sci. 2014;73(1):57\u201362. https:\/\/doi.org\/10.1016\/j.jdermsci.2013.08.011.","journal-title":"J Dermatol Sci"},{"key":"1436_CR25","doi-asserted-by":"publisher","unstructured":"Quintero OP, Arrondo AP, Veleiro B. Rapid response to omalizumab in 3 cases of delayed pressure urticaria. J Allergy Clin Immunol Pract. 2017;5(1):179\u201380. https:\/\/doi.org\/10.1016\/j.jaip.2016.07.016.","DOI":"10.1016\/j.jaip.2016.07.016"},{"key":"1436_CR26","unstructured":"Novartis Pharmaceuticals. Study of efficacy and safety of ligelizumab in adolescents and adults with chronic inducible urticaria who remain symptomatic despite treatment with H1-antihistamines (PEARL-PROVOKE). Clinicaltrials.gov. 2024. https:\/\/clinicaltrials.gov\/study\/NCT05024058. Accessed 06 Feb 2025."},{"issue":"1","key":"1436_CR27","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jaci.2024.01.028","volume":"154","author":"M Maurer","year":"2024","unstructured":"Maurer M, Casale TB, Saini SS, Ben-Shoshan M, Gim\u00e9nez-Arnau AM, Bernstein JA, Yagami A, Stjepanovic A, Radin A, Staudinger HW, Patel N, Amin N, Akinlade B, Fan C, Bauer D, Yancopoulos GD, Patel K, Mannent LP, Laws E. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials. J Allergy Clin Immunol. 2024;154(1):184\u201394. https:\/\/doi.org\/10.1016\/j.jaci.2024.01.028.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"1436_CR28","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.3390\/ph17111499","volume":"17","author":"R Asero","year":"2024","unstructured":"Asero R, Calzari P, Vaienti S, Cugno M. Therapies for chronic spontaneous urticaria: present and future developments. Pharmaceuticals (Basel). 2024;17(11):1499. https:\/\/doi.org\/10.3390\/ph17111499.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"10","key":"1436_CR29","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.3390\/ph15101246","volume":"15","author":"S Nochaiwong","year":"2022","unstructured":"Nochaiwong S, Chuamanochan M, Ruengorn C, Thavorn K. Evidence gaps in clinical trials of pharmacologic treatment for H1-antihistamine-refractory chronic spontaneous urticaria: a systematic review and future perspectives. Pharmaceuticals (Basel). 2022;15(10):1246. https:\/\/doi.org\/10.3390\/ph15101246.","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01436-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01436-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01436-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T08:45:03Z","timestamp":1746607503000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01436-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1436"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01436-9","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"assertion":[{"value":"17 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study concept and design: A.C.P.V., A.C.V.S.J., and C.M.D.M. Acquisition, analysis, or interpretation of data: A.P.C., C.M.D.M., L.M.B., and A.C.P.V. Drafting of the manuscript: A.C.P.V., A.C.V.S.J., A.C.F.F.S., M.P., and G.G.L. Critical revision of the manuscript: A.C.P.V., A.C.V.S.J., A.P.C., L.M.B., A.F.F.S., C.M.D.M., M.P., and G.G.L. Study supervision: F.V.Z. All authors have read and approved the final version of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"No funds, grants, or other support was received.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The data that support the findings of this study are available within the material of this article and the supplementary material.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}}]}}